Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study.
Medd PG, Peniket AJ, Littlewood TJ, Pearce R, Perry J, Kirkland KE, Shaw BE, Potter MN, Craddock CF, Milligan DW, Fielding AK, Marks DI, Cook G; British Society of Blood and Marrow Transplantation. Medd PG, et al. Bone Marrow Transplant. 2013 Jul;48(7):982-7. doi: 10.1038/bmt.2012.261. Epub 2013 Jan 14. Bone Marrow Transplant. 2013. PMID: 23318533 Clinical Trial.
Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD.
Dignan FL, Greenblatt D, Cox M, Cavenagh J, Oakervee H, Apperley JF, Fielding AK, Pagliuca A, Mufti G, Raj K, Marks DI, Amrolia P, Peniket A, Medd P, Potter MN, Shaw BE, Scarisbrick JJ. Dignan FL, et al. Bone Marrow Transplant. 2012 Jun;47(6):824-30. doi: 10.1038/bmt.2011.186. Epub 2011 Sep 19. Bone Marrow Transplant. 2012. PMID: 21927038 Clinical Trial.
Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
Brierley CK, Jones FM, Hanlon K, Peniket AJ, Hatton C, Collins GP, Schuh A, Medd P, Clark A, Ward J, Chaganti S, Malladi R, Parker A, Craddock C, Danby R, Rocha V. Brierley CK, et al. Br J Haematol. 2019 Feb;184(4):547-557. doi: 10.1111/bjh.15685. Epub 2018 Nov 22. Br J Haematol. 2019. PMID: 30467838 Free article. Clinical Trial.
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group. Russell NH, et al. J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215358 Clinical Trial.
22 results